HK1050008A1 - Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors - Google Patents
Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitorsInfo
- Publication number
- HK1050008A1 HK1050008A1 HK03102259.9A HK03102259A HK1050008A1 HK 1050008 A1 HK1050008 A1 HK 1050008A1 HK 03102259 A HK03102259 A HK 03102259A HK 1050008 A1 HK1050008 A1 HK 1050008A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- heterobicyclic
- sulfonamides
- receptor inhibitors
- adp receptor
- platelet adp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20207500P | 2000-05-05 | 2000-05-05 | |
US23045600P | 2000-09-06 | 2000-09-06 | |
PCT/US2001/014441 WO2001085722A1 (en) | 2000-05-05 | 2001-05-04 | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1050008A1 true HK1050008A1 (en) | 2003-06-06 |
Family
ID=26897333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03102259.9A HK1050008A1 (en) | 2000-05-05 | 2003-03-28 | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1278744A1 (en) |
JP (1) | JP2003532728A (en) |
AU (1) | AU2001264566A1 (en) |
CA (1) | CA2408156A1 (en) |
HK (1) | HK1050008A1 (en) |
WO (1) | WO2001085722A1 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU98003A (en) | 2001-06-11 | 2006-03-03 | Biovitrum Ab. | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
EA008835B1 (en) * | 2002-06-20 | 2007-08-31 | Биовитрум Аб | Substituted sulfone and sulfonamides and pharmaceutical compositions based thereon useful for the treatment of obesity, type ii diabetes cns disorders |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
SE0301446D0 (en) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
UY30048A1 (en) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | SUBSTITUTED DERIVATIVES OF THE N, 2- (1H-BENZIMIDAZOL-1-IL) ACETAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS |
WO2007093507A1 (en) * | 2006-02-13 | 2007-08-23 | F. Hoffmann-La Roche Ag | Heterobicyclic sulfonamide derivatives for the treatment of diabetes |
TWI433839B (en) | 2006-08-11 | 2014-04-11 | Neomed Inst | New benzimidazole derivatives 290 |
AR071523A1 (en) * | 2008-04-30 | 2010-06-23 | Merck Serono Sa | FUSIONATED BICYCLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, THE COMPOSITE TO BE USED AS A MEDICINAL PRODUCT IN THE TREATMENT AND PROFILAXIS OF DISEASES, A PHARMACEUTICAL COMPOSITION AND A SET THAT INCLUDES SEPARATE PACKAGES OF THE COMPOUND AND OF AN INGREDIENT |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EA036592B1 (en) | 2012-06-13 | 2020-11-26 | Инсайт Холдингс Корпорейшн | Substituted tricyclic compounds as fgfr inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MX371017B (en) | 2014-02-03 | 2020-01-13 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridine inhibitors of ror-gamma. |
SG11201702362SA (en) | 2014-10-14 | 2017-04-27 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
ES2895769T3 (en) | 2015-02-20 | 2022-02-22 | Incyte Corp | Bicyclic heterocycles as FGFR inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
KR20180014832A (en) | 2015-06-22 | 2018-02-09 | 액테리온 파마슈티칼 리미티드 | NADPH oxidase 4 inhibitor |
ES2856931T3 (en) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | ROR-gamma modulators |
KR20180086221A (en) | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Regulators of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
MX2020000887A (en) | 2017-07-24 | 2020-07-22 | Vitae Pharmaceuticals Llc | Inhibitors of rorï. |
CA3099287A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CR20220169A (en) | 2019-10-14 | 2022-10-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
BR112022010664A2 (en) | 2019-12-04 | 2022-08-16 | Incyte Corp | DERIVATIVES OF A FGFR INHIBITOR |
CN113959911A (en) * | 2020-07-20 | 2022-01-21 | 深圳迈瑞生物医疗电子股份有限公司 | Detection method and reagent for resisting platelet aggregation interference and application thereof |
CN113959912A (en) * | 2020-07-20 | 2022-01-21 | 深圳迈瑞生物医疗电子股份有限公司 | Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB517272A (en) * | 1938-06-03 | 1940-01-25 | May & Baker Ltd | The preparation of new therapeutically useful heterocyclic compounds |
FI91859C (en) * | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogue method for the preparation of an active benzothiazole derivative as an antiallergic agent |
DE3916469A1 (en) * | 1989-05-20 | 1990-11-22 | Basf Ag | SULPHONAMID |
EP1047699A1 (en) * | 1998-01-15 | 2000-11-02 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
-
2001
- 2001-05-04 JP JP2001582323A patent/JP2003532728A/en not_active Withdrawn
- 2001-05-04 EP EP01938998A patent/EP1278744A1/en not_active Withdrawn
- 2001-05-04 WO PCT/US2001/014441 patent/WO2001085722A1/en not_active Application Discontinuation
- 2001-05-04 CA CA002408156A patent/CA2408156A1/en not_active Abandoned
- 2001-05-04 AU AU2001264566A patent/AU2001264566A1/en not_active Abandoned
-
2003
- 2003-03-28 HK HK03102259.9A patent/HK1050008A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003532728A (en) | 2003-11-05 |
WO2001085722A1 (en) | 2001-11-15 |
AU2001264566A1 (en) | 2001-11-20 |
EP1278744A1 (en) | 2003-01-29 |
CA2408156A1 (en) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1050008A1 (en) | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors | |
AR028253A1 (en) | INHIBITORS OF THE GLUCOGENO FOSFORILASA | |
MA26819A1 (en) | PTERIDINONES AS KINASE INHIBITORS. | |
NO20040469L (en) | Heterocyclic compounds and their preparation and use | |
NO20032277L (en) | Aminothiazoles and their use as adenosine receptor antagonists | |
NO20023713D0 (en) | 2-benzothiazolyl-urea derivatives and their use as protein kinase inhibitors | |
NO20031109L (en) | drinking | |
PT1370553E (en) | RHOQUINASE INHIBITORS | |
HU0101158D0 (en) | Use of glycogen phosphorylase inhibitors | |
IL161516A0 (en) | Benzimidazoles useful as protein kinase inhibitors | |
MXPA03006420A (en) | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase. | |
ATE555761T1 (en) | ABSORBENT ARTICLE | |
DE60214783D1 (en) | Absorbent article | |
CY2007002I1 (en) | O-CARBOXYARYLIPOCUTATED BIFINYLUREAS AS RAF KINASE INHIBITORS | |
DK1280801T3 (en) | Hydantoin-containing glucokinase activators | |
PT1226136E (en) | TIROSIN KINASE INHIBITORS | |
GB0025782D0 (en) | Use of inhibitors | |
IS6802A (en) | 3-arylindole derivatives and their use as CB2 receptor agonists | |
NO20024064D0 (en) | mooring | |
DE60111451D1 (en) | Topcoat composition | |
ID30187A (en) | DONGKRAK KIND OF PANTAGRAF | |
DE50101079D1 (en) | FASTENABLE CONTAINER | |
EE05020B1 (en) | The pharmaceutical composition of G1buride | |
ATE456657T1 (en) | AROMATIC METHYL TRANSFERASES AND THEIR USE | |
DK1142477T3 (en) | Controlled release compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Change of ownership |
Owner name: PORTOLA PHARMACEUTICALS, INC. Free format text: FORMER OWNER(S): MILLENNIUM PHARMACEUTICALS, INC |